Quratis Inc.
Research Quratis Inc. (348080.KQ) on Bullrun: market cap KRW 42.42B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker348080.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 42.42B
- Financial periodQ2 2026
- RevenueKRW 320.27M
- Net income-KRW 3.02B
- Free cash flow-KRW 2.42B
- Gross margin-545.4%
Valuation Snapshot
latest market cap is KRW 42.42B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 42.42B | n/a | n/a | n/a |
Dividend history
About Quratis Inc.
Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; QTP104, a next-generation mRNA vaccine; CPP (Cell Penetrating Peptide) Platform, a cell and bacterial penetration peptide drug delivery platform technology; and Peptide Nucleic Acid (PNA), a synthetic analogue of DNA in which the deoxyribose phosphate backbone. The company also offers drugs contract development and manufacturing services. Quratis Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Quratis Inc.'s market cap?
Quratis Inc.'s market capitalization is KRW 42.42B.
What does Quratis Inc. do?
Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; QTP104, a next-generation mRNA vaccine; CPP (Cell Penetrating Peptide) Platform, a cell and bacterial penetration peptide drug delivery platform technology; and Peptide Nucleic Acid (PNA), a synthetic analogue of DNA in which the deoxyribose phosphate backbone. The company also offers drugs contract development and manufacturing services. Quratis Inc. was incorporated in 2016 and is based in Cheongju-si, South Korea.